GlaxoSmithKline Anti-Nausea Drug Linked to Arrhthymias

U.S. health regulators said they are reviewing the safety of GlaxoSmithKline's anti-nausea drug Zofran to ascertain whether there is a potential risk of abnormal heart rhythm. The drug may increase the risk of developing abnormal changes in the electric activity of the heart, leading to a potentially fatal heart rhythm, the U.S. Food and Drug Administration said in a statement. GSK will be required to conduct a study on whether Zofran could prolong a patient's QT interval, a measure of heart rhythm. The results of the study are expected in summer of 2012.